1046492-36-7

Upstream product

• 1046492-30-1 4-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-N-(2,2-dimethoxy-ethyl)-benzamide 
• 193418-22-3 4-(2-((tert-butyldimethylsilyl)oxy)ethyl)benzoic acid 
• 1046492-31-2 N-(2,2-dirnethoxy-ethyl)-4-(2-hydroxy-ethyl)-benzamide 
• 189012-93-9 7-(2-aminoethyl)-4-hydroxy-1,3-benzothiazol-2(3H)-one hydrochloride 
• 1046492-34-5 N-(2,2-dimethoxyethyl)-4-(2-oxoethyl)benzamide 

Downstream Products

• 1046492-32-3 {2-[4-(2,2-dimethoxy-ethylcarbamoyl)-phenyl]-ethyl}-[2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethyl]-carbamic acid tert-butyl ester 
• 1046492-37-8 [2-(4-hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethyl]-{2-[4-(2-oxo-ethylcarbamoyl)-phenyl]-ethyl}-carbamic acid tert-butyl ester 

Relevant academic research and scientific papers

BICYCLOR [2.2.1] HEPT-7-YLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES AND CONDITIONS IN WHICH M3 MUSCARINIC RECEPTOR ACTIVITY AND BETA-ADRENERGIC ACTIVITY ARE IMPLICATED

The present invention relates to compounds of formula (I) having muscarinic M3 receptor and β-adrenergic receptor modulating activity; wherein R1, R2, R3 and X are as defined herein.

NEW CHEMICAL COMPOUNDS

The present invention provides compounds of formula (I) having muscarinic M3 receptor and β-adrenergic receptor modulating activity; processes for their preparation and their use in therapy; wherein A, R1, R2, R3 and Rsup